Related Experiment Videos
Structural and functional similarities between HIV-1 reverse transcriptase and the Escherichia coli RNA polymerase
A M Szilvay1, B Stern, A Blichenberg
1Department of Molecular Biology, University of Bergen, HIB, P.O. Box 7800, N-5020, Bergen, Norway. anne.szilvay@mbi.uib.no
FEBS Letters
|November 1, 2000
Summary
Four antibodies targeting HIV-1 reverse transcriptase (RT) also bind to a similar region on E. coli RNA polymerase (RNAP). This cross-reactivity suggests structural similarities and impacts polymerase activity.
Area of Science:
- Molecular Biology
- Virology
- Biochemistry
Background:
- Monoclonal antibodies (MAbs) are crucial tools for identifying specific protein epitopes.
- HIV-1 reverse transcriptase (RT) and E. coli RNA polymerase (RNAP) are essential enzymes with distinct functions.
- Cross-reactivity between antibodies and different proteins can reveal shared structural motifs.
Purpose of the Study:
- To investigate potential cross-reactivity between MAbs against HIV-1 RT and bacterial RNAP.
- To identify the specific regions involved in this observed cross-reactivity.
- To determine the functional consequences of this cross-reactivity on enzyme activity.
Main Methods:
- Production and characterization of four MAbs specific for HIV-1 RT.
- Binding assays using MAbs to assess cross-reactivity with E. coli RNAP.
- Bioinformatic analysis to compare amino acid sequences of RT and RNAP.
- Epitope mapping using RT mutants and MAb-binding studies.
- Enzyme inhibition assays to evaluate the effect of MAbs on RT and RNAP activity.
Main Results:
- Four anti-RT MAbs demonstrated cross-reactivity with the beta' subunit of E. coli RNAP.
- Sequence analysis identified similarities between the RT epitope (residues 294-305) and two regions in the RNAP beta' subunit.
- Epitope mapping localized the cross-reactive site on RNAP beta' to amino acids 652-663.
- One MAb inhibited both HIV-1 RT and E. coli RNAP polymerase activity in a dose-dependent manner.
Conclusions:
- A structural similarity exists between a specific epitope on HIV-1 RT and a region on E. coli RNAP beta' subunit.
- This cross-reactivity can be exploited to inhibit the activity of both enzymes.
- The findings highlight the potential for cross-reactivity in antibody-based research and therapeutics.